Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas
This article was originally published in Pharmaceutical Approvals Monthly
Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That’s the strategy management laid out for investors during an R&D day in New York April 8.
You may also be interested in...
Agios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011